Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 2.54 USD -4.15% Market Closed
Market Cap: 2.2B USD

Net Margin
Immunitybio Inc

-1 310.3%
Current
-73 211.1%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 310.3%
=
Net Income
-409.1m
/
Revenue
31.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Immunitybio Inc
NASDAQ:IBRX
2.2B USD
-1 310%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.2B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Immunitybio Inc
Glance View

ImmunityBio, Inc., born from the vision of tackling some of the most stubborn challenges in modern medicine, operates at the cutting edge of biotechnology. Founded by Dr. Patrick Soon-Shiong, a renowned physician and surgeon, the company is driven by the mission to develop innovative immunotherapies that unlock the potential of the human immune system to fight cancer and infectious diseases. At the heart of ImmunityBio’s operations is their proprietary platform, designed to activate multiple components of the immune system, thereby aiming to enhance the body’s ability to combat malignant cells and improve patient outcomes. The company's diverse portfolio includes tumor-targeting antibodies, natural killer (NK) cell therapies, and vaccine platforms, underscoring its commitment to addressing diseases from multiple angles. ImmunityBio generates revenue by taking these biotechnology innovations from the lab to the marketplace. Partnerships and collaborations with larger pharmaceutical companies play a significant role in advancing their pipeline and bringing therapies to market. For example, strategic alliances help streamline the extensive and costly clinical trial process, enhancing the speed and efficiency of drug development. Additionally, the company is invested in establishing licensing agreements, which allow them to leverage their proprietary technology in collaboration with other industry players. Through these initiatives, ImmunityBio not only seeks to accelerate the commercialization of its therapies but also aims to carve out a sustainable financial path in the ever-competitive healthcare landscape.

IBRX Intrinsic Value
12.63 USD
Undervaluation 80%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 310.3%
=
Net Income
-409.1m
/
Revenue
31.2m
What is the Net Margin of Immunitybio Inc?

Based on Immunitybio Inc's most recent financial statements, the company has Net Margin of -1 310.3%.

Back to Top